Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way.
Last Closing Price
February 14, 2018
To view the prospectus for , or any offering listed on ClickIPO,
download the ClickIPO app...
or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC P. O. Box 21154, Mesa, AZ 85277